Form 4: Heron Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, exercised stock options, acquiring 12,500 shares of common stock on June 6, 2024.
Summary
- On June 6, 2024, William P. Forbes, the EVP and Chief Development Officer of Heron Therapeutics, exercised restricted stock units.
- This transaction resulted in the acquisition of 12,500 shares of common stock.
- Following the transaction, Forbes directly owns 95,374 shares of Heron Therapeutics common stock.
- Forbes also holds 37,500 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine transaction. It doesn't inherently indicate positive or negative prospects for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares, but it's unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Exercise of restricted stock units and acquisition of common stock. |
| 06/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.